LeonaBio
LONALONA · Stock Price
Historical price data
Overview
LeonaBio, a rebranded entity from Athira Pharma, is a clinical-stage biotech focused on oncology and neurology. Its strategy pivoted decisively in late 2025 with the in-licensing of the Phase 3 breast cancer candidate lasofoxifene and a financing package of up to $236 million. The company's mission is to advance targeted, small molecule therapeutics for specific, underserved patient populations, leveraging differentiated mechanisms of action to address critical resistance pathways in cancer and neurodegeneration.
Technology Platform
Strategic application of distinct small molecule mechanisms targeting validated pathways: ESR1 in endocrine-resistant breast cancer and the HGF/MET neurotrophic system in ALS.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ATH-1017 | Alzheimer Disease | Phase 2/3 | |
| ATH-1017 + Placebo | Alzheimer Disease | Phase 2/3 | |
| ATH-1017 + Placebo | Alzheimer Disease | Phase 2 | |
| ATH-1017 + Placebo | Parkinson Disease Dementia | Phase 2 | |
| ATH-1105 + Placebo | Healthy Volunteers | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Lasofoxifene competes with oral SERDs like elacestrant in the ESR1-mutant breast cancer segment. ATH-1105 enters a competitive ALS field with diverse mechanisms, requiring clear differentiation on efficacy or safety to succeed.